NuVasive (NUVA) Receives Media Sentiment Score of -0.08

News stories about NuVasive (NASDAQ:NUVA) have been trending somewhat negative recently, according to AlphaOne Sentiment Analysis. The research group, a service of Accern, scores the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. AlphaOne ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. NuVasive earned a coverage optimism score of -0.08 on AlphaOne’s scale. AlphaOne also assigned news coverage about the medical device company an impact score of 0 out of 100, indicating that recent press coverage is extremely unlikely to have an effect on the stock’s share price in the immediate future.

Here are some of the media stories that may have impacted AlphaOne Sentiment’s analysis:

Shares of NuVasive (NASDAQ:NUVA) traded down 0.90% during trading on Friday, hitting $75.02. 196,064 shares of the stock traded hands. The stock has a 50 day moving average of $74.23 and a 200 day moving average of $68.92. The firm has a market cap of $3.80 billion, a price-to-earnings ratio of 108.72 and a beta of 0.86. NuVasive has a 52-week low of $49.87 and a 52-week high of $76.31.

NuVasive (NASDAQ:NUVA) last issued its quarterly earnings results on Thursday, February 9th. The medical device company reported $0.53 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.51 by $0.02. NuVasive had a return on equity of 12.26% and a net margin of 3.29%. The firm earned $271.10 million during the quarter, compared to analysts’ expectations of $261.25 million. During the same period in the previous year, the business earned $0.35 earnings per share. The firm’s revenue for the quarter was up 25.9% on a year-over-year basis. Analysts expect that NuVasive will post $2.02 EPS for the current year.

Several analysts recently commented on the stock. Needham & Company LLC reissued a “hold” rating on shares of NuVasive in a research report on Friday, February 10th. Jefferies Group LLC increased their price objective on shares of NuVasive to $84.00 in a research report on Friday, February 10th. Barclays PLC increased their price objective on shares of NuVasive to $80.00 in a research report on Friday, February 10th. BMO Capital Markets reissued a “buy” rating and set a $82.00 price objective on shares of NuVasive in a research report on Tuesday, April 11th. Finally, Canaccord Genuity reissued a “buy” rating and set a $82.00 price objective on shares of NuVasive in a research report on Tuesday, February 21st. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and ten have assigned a buy rating to the stock. NuVasive currently has an average rating of “Buy” and an average target price of $72.42.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece can be accessed at https://sportsperspectives.com/2017/04/21/nuvasive-nuva-receives-media-sentiment-score-of-0-08.html.

In other NuVasive news, Director Lesley H. Howe sold 6,049 shares of the company’s stock in a transaction on Tuesday, February 14th. The stock was sold at an average price of $73.26, for a total value of $443,149.74. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Jason Hannon sold 24,840 shares of the company’s stock in a transaction on Wednesday, March 8th. The shares were sold at an average price of $74.22, for a total value of $1,843,624.80. The disclosure for this sale can be found here. 4.70% of the stock is currently owned by insiders.

NuVasive Company Profile

Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.

5 Day Chart for NASDAQ:NUVA

Receive News & Ratings for NuVasive Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply